Who are Adalimumab+Methotrexate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infliximab (INF) + MTX, DB, Adalimumab with methotrexate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adalimumab-methotrexate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Adalimumab+Methotrexate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adalimumab+Methotrexate (Adalimumab+Methotrexate) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor + DMARD combination. Area: Immunology.

phase 3 TNF-alpha inhibitor + DMARD combination TNF-alpha receptor; dihydrofolate reductase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Adalimumab+Methotrexate (Adalimumab+Methotrexate) — Hospital San Carlos, Madrid. Adalimumab blocks TNF-alpha to reduce inflammation, while methotrexate inhibits dihydrofolate reductase and suppresses immune cell proliferation, together providing synergistic anti-inflammatory and immunosuppressive effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adalimumab+Methotrexate TARGET	Adalimumab+Methotrexate	Hospital San Carlos, Madrid	phase 3	TNF-alpha inhibitor + DMARD combination	TNF-alpha receptor; dihydrofolate reductase
Infliximab (INF) + MTX, DB	Infliximab (INF) + MTX, DB	Bristol-Myers Squibb	phase 3	TNF-alpha inhibitor + DMARD combination	TNF-alpha receptor; dihydrofolate reductase
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor + DMARD combination class)

Bristol-Myers Squibb · 1 drug in this class
Hospital San Carlos, Madrid · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adalimumab+Methotrexate — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab-methotrexate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing